ATE362545T1 - Screening-verfahren für substanzen zur behandlung von diabetes - Google Patents

Screening-verfahren für substanzen zur behandlung von diabetes

Info

Publication number
ATE362545T1
ATE362545T1 AT02804896T AT02804896T ATE362545T1 AT E362545 T1 ATE362545 T1 AT E362545T1 AT 02804896 T AT02804896 T AT 02804896T AT 02804896 T AT02804896 T AT 02804896T AT E362545 T1 ATE362545 T1 AT E362545T1
Authority
AT
Austria
Prior art keywords
activity
diabetes
pai
substances
treatment
Prior art date
Application number
AT02804896T
Other languages
English (en)
Inventor
Kazuhiko Hanashiro
Yoshikuni Nagamine
Original Assignee
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung
Application granted granted Critical
Publication of ATE362545T1 publication Critical patent/ATE362545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02804896T 2001-12-14 2002-12-13 Screening-verfahren für substanzen zur behandlung von diabetes ATE362545T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130007.8A GB0130007D0 (en) 2001-12-14 2001-12-14 Screening method for agents useful in treating diabetes

Publications (1)

Publication Number Publication Date
ATE362545T1 true ATE362545T1 (de) 2007-06-15

Family

ID=9927673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804896T ATE362545T1 (de) 2001-12-14 2002-12-13 Screening-verfahren für substanzen zur behandlung von diabetes

Country Status (8)

Country Link
US (1) US20050037956A1 (de)
EP (1) EP1458883B1 (de)
JP (1) JP2005512546A (de)
AT (1) ATE362545T1 (de)
AU (1) AU2002366442A1 (de)
DE (1) DE60220185D1 (de)
GB (1) GB0130007D0 (de)
WO (1) WO2003052124A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249670A1 (en) * 2000-04-03 2001-10-15 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1

Also Published As

Publication number Publication date
GB0130007D0 (en) 2002-02-06
AU2002366442A1 (en) 2003-06-30
AU2002366442A8 (en) 2003-06-30
DE60220185D1 (de) 2007-06-28
WO2003052124A2 (en) 2003-06-26
JP2005512546A (ja) 2005-05-12
EP1458883B1 (de) 2007-05-16
US20050037956A1 (en) 2005-02-17
WO2003052124A3 (en) 2003-11-06
EP1458883A2 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
IL125662A0 (en) Method of detecting influenza virus and compounds for use therein
DE69728585D1 (de) Mittel gegen Juckreiz
MY138289A (en) Pharmaceutical compositions
TR200100146T2 (tr) Antidepresan etkiye sahip madde
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
EE04356B1 (et) aP2 inhibiitor kasutamiseks suhkurtõve ravis ja seda sisaldav ravimkoostis
DE60326259D1 (de) Neue fructosylpeptidoxidase und deren nutzung
GB9924957D0 (en) Novel treatment
WO2000034511A3 (de) Peptid screening test zum nachweis von ass
DK1075277T3 (da) Fremgangsmåder til detektion og inhibering af angiogenese
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
ATE274346T1 (de) Tnf-alpha konvertierendes enzym
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
SE0202157D0 (sv) Methods for identification of compounds modulating insulin resistance
EP1509220A4 (de) Pharmazeutische zusammensetzung zur behandlung von seborrhoe mit 4-hydroxy-5-methoxy-4-2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-on
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60220185D1 (de) Screening-verfahren für substanzen zur behandlung von diabetes
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
WO1999001567A3 (en) Methods and compositions for a deubiquitinating enzyme and variants thereof
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties